URO 17

URO17 is a highly sensitive and specific non-invasive urine test designed to detect both low-grade and high-grade bladder cancer with impressive accuracy. By identifying URO17 protein expression through standard immunohistochemistry systems, it serves as a powerful tool for early detection, risk assessment, and diagnostic decision-making. Ideal for patients with hematuria, those under NMIBC follow-up, and high-risk groups, URO17 offers the potential to significantly reduce diagnostic uncertainty and improve clinical outcomes.

Please Log In to access Additional Details and documents ..

• Clinical applications: Suitable for patients with hematuria, follow-up of non-muscle invasive bladder cancer (NMIBC), and high-risk populations such as smokers, individuals with chemical exposure, or those with a family history of bladder cancer.
  
  

• About URO17:
  
  

• Non-invasive urine-based test
  
  

• 100% sensitivity and 96% specificity
  
  

• Fully compatible with standard immunohistochemistry systems
  
  

• Detects both low-grade and high-grade bladder cancer
  
  

• Considered to have gold-standard potential in diagnostic workflows
  
  

• Risk stratification guidance:
  
  

• Negative cytology / negative URO17: No to low risk of bladder cancer
  
  

• Atypical cytology / negative URO17: No to low risk of bladder cancer
  
  

• Negative cytology / high URO17 expression: Standard diagnostic workup recommended
  
  

• Atypical cytology / high URO17 expression: Standard diagnostic workup recommended
  
  

If you’d like this adapted into a patient-friendly version, a marketing one-pager, or aligned stylistically with the ColonAiQ summary for a combined portfolio, I can prepare that as well.